Inside the research
NeoGenomics, Inc.
NEO Research profile · latest available data
Price overview
$19.33
▼ -0.23 (-1.2%)
| 52w hi | $19.91 |
|---|---|
| 52w lo | $7.19 |
| Vol | 2.02M |
| As of | 25 Sep 2026 |
The Verdict
Our score +0.26
| Short | +0.46 |
|---|---|
| Medium | +0.35 |
| Long | -0.31 |
computed 2026-09-27
Key fundamentals
NeoGenomics, Inc.
Healthcare · Diagnostics & Research
| Market cap | $2.48B |
|---|---|
| Enterprise value | $2.79B |
| Forward P/E | 57.16x |
| EV / EBITDA | 114.54x |
| P / S (ttm) | 3.28x |
| Profit margin | -6.8% |
| Return on equity | -6.3% |
| Revenue growth | +11.2% |
| Debt / equity | 57.06 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | -0.04 | |
| Sector | +0.08 | |
| Technical | +0.32 | |
| Earnings | +0.00 | |
| Sentiment | -0.02 |
macro × 1.00 · 2026-09-27
Business overview
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Risk Metrics
| Beta vs SPX | 1.23 |
|---|---|
| Corr SPX | 0.29 |
| Annual vol | 67.3% |
| Annual ret | +32.0% |
| Sharpe | 0.48 |
| Max DD | -74.0% |
Window: 504 trading days (504 obs)
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-08-11 | Officer / Director Change | read |
| 2026-07-28 | Earnings Release, Exhibits | read |
| 2026-07-20 | Reg FD Disclosure, Other Material Event… | read |
| 2026-06-25 | Officer / Director Change, Reg FD Disclosure… | read |
| 2026-06-22 | Material Agreement, Material Obligation… | read |
| 2026-06-17 | Other Material Event, Exhibits | read |
| 2026-06-15 | Other Material Event, Exhibits | read |
| 2026-05-22 | Officer / Director Change, Shareholder Vote… | read |
| 2026-04-28 | Earnings Release, Exhibits | read |
| 2026-02-17 | Earnings Release, Exhibits | read |
| 2026-01-12 | Earnings Release, Officer / Director Change… | read |
| 2025-12-30 | Officer / Director Change, Exhibits | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-04 | Aunan Greg D | Chief Accounting Officer | Sell | 20.00K | $321.40K |
Flow & Concentration
| Insider 180d net | -$321.40K |
|---|---|
| Insider buys / sells | 0 / 1 |
| Insider bias | Neutral |
| 13F holders | 7 |
| Top-5 share | 98.9% |
| HHI | 4,140 (concentrated) |
Top Holders
| Holder | Value | Shares |
|---|---|---|
| State Street Corp | $78.26M | 5.36M |
| Capital Research / Capital World | $40.97M | 2.81M |
| AQR Capital Management | $12.15M | 832.72K |
| Fidelity / FMR LLC | $3.42M | 234.15K |
| Millennium Management | $2.38M | 2.53M |
| Citadel Advisors | $1.55M | 106.50K |
| T. Rowe Price Group | $2.79K | 191.50K |
As of 2026-06-30
SEC Filings
The Long Run
FY 2011–2025 · 15 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $5.00M | +0.0% | |
| Gross profit | $314.29M | +23.8% | |
| Operating income | -$115.88M | +48.5% | |
| Net income | -$108.03M | +129.9% | |
| Cash from ops | $7.02M | +217.6% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $19.56 | $19.75 | $18.87 | $19.33 | 2.02M |
| Sep 24 | $18.47 | $19.73 | $18.40 | $19.56 | 2.95M |
| Sep 23 | $18.69 | $19.08 | $18.27 | $18.36 | 2.91M |
| Sep 22 | $19.28 | $19.60 | $18.83 | $18.89 | 4.00M |
| Sep 21 | $19.92 | $20.05 | $19.28 | $19.41 | 1.44M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →